Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.27181 ↗At a glance
Journal article in Pediatric Pulmonology, 2024. Written by Ceren Ayça Yıldız and 16 co-authors. Institution: Division of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Turkey. Major MEDLINE topics: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: None.
Abstract (original language)
Background
Cystic fibrosis (CF) is an autosomal recessive disease caused by variants of CFTR gene. Over 2000 variants have been identified, and new drugs called CFTR modulators have been developed to target specific defects in the CFTR protein. However, these drugs are only suitable for patients with certain variants of CFTR , and eligibility rates vary depending on race and geographical region. This study aimed to reveal the detailed genotype and clinical characteristics of people with CF (pwCF) at our center in Turkey, a developing country, who are not eligible for CFTR modulators.
Methods
A total of 445 pwCF followed up at Marmara University were reviewed retrospectively. Variants of the patients ineligible to CFTR modulators were classified based on American College of Medical Genetics guidelines, CFTR classification, the change in the encoded protein, and the variant type.
Results
The study revealed that 139 (31.2%) patients weren't eligible for CFTR modulators. There were 60 different variants in the 276 alleles, as two were missing. The majority of patients had missense or nonsense variants, and that the most common variant was c.1545_1546del, which can be said unique to this geography.
Conclusion
The study highlights the importance of detecting the variants of ineligible patients in detail to guide future approaches for more targeted and effective interventions in CF care. Testing the effectiveness of CFTR modulators for rare or newly occurring variants is crucial to ensure equal access for pwCF to these therapies from different racial backgrounds and ethnic minorities.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Turkey.
- Department of Medical Genetics, Marmara University School of Medicine, Istanbul, Turkey.
ORCID profiles: Ceren Ayça Yıldız, Merve Selçuk Balcı, Şeyda Karabulut, Mine Yüksel Kalyoncu, Pınar Ergenekon
Funding
- None
Cite
APA
Yıldız, C. A., Selçuk Balcı, M., Karabulut, Ş., Başer, Z. M., Yüksel Kalyoncu, M., Metin Çakar, N., Akkitap Yiğit, M. M., Baysal, E. E., Özdemircioğlu, F., Uzunoğlu, B., Taştan, G., Ergenekon, P., Gökdemir, Y., Erdem Eralp, E., Karakoç, F., Ata, P., & Karadağ, B. (2024). Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27181
Vancouver
Yıldız CA, Selçuk Balcı M, Karabulut Ş, Başer ZM, Yüksel Kalyoncu M, Metin Çakar N, et al. Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27181
BibTeX
@article{Yldz2024,
author = {Yıldız, Ceren Ayça and Selçuk Balcı, Merve and Karabulut, Şeyda and Başer, Zeynep Münteha and Yüksel Kalyoncu, Mine and Metin Çakar, Neval and Akkitap Yiğit, Müge Merve and Baysal, Eda Esra and Özdemircioğlu, Fulya and Uzunoğlu, Burcu and Taştan, Gamze and Ergenekon, Pınar and Gökdemir, Yasemin and Erdem Eralp, Ela and Karakoç, Fazilet and Ata, Pınar and Karadağ, Bülent},
title = {Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.27181}
}
EUVIMED